Pharmacokinetic and Stability Analysis of an Inhalable Formulation of Camptothecin for the Treatment of Lung Cancer

This work focused on creating an inhalable dry-powder camptothecin (CPT) formulation that could be tested in vivo and potentially developed into a lung-cancer therapeutic. CPT and analogs of CPT have been shown to be effective in treating lung cancers, but the physical properties of CPT have made it difficult to formulate into a deliverable therapeutic. Due to its extremely fast rate of crystallization, CPT has very poor aqueous solubility, which has limited its therapeutic potential and its use in the clinic. Bend Research created a spray-dried formulation containing nanocrystalline CPT and 10,000 molecular weight (MW) dextran (Dex10), which was exposed to elevated temperatures in an informal stability study at PPD and tested in vivo in a rodent inhalation model at Lovelace Respiratory Research Institute (LRRI).